Compare Heron Therapeutics Inc (HRTX) vs Skyworks Solutions Inc (SWKS) Price & Performance

Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.

The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.

Skyworks Solutions (SWKS) trades at $83.43, up 0.88% on the day, with a neutral technical signal despite bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though revenue and net income margins have declined year-over-year. The pending Qorvo merger, expected to close in 2026, represents a significant strategic move with $500 million in projected synergies, driving recent stock momentum and analyst optimism.

The investment case balances merger synergies and market expansion against declining profitability and integration risks. With 60% of analysts rating SWKS a Buy and a consensus price target of $78.80 (below current price), near-term upside appears limited. Key risks include execution of the Qorvo integration, competitive pressures in semiconductors, and macroeconomic headwinds affecting consumer electronics demand.